Novavax (NVAX) announced that James Young, PhD, is retiring as Chair of the Board and Margaret McGlynn, RPh, has been appointed as his successor. The Company also appointed John Shiver, PhD, to its board as an independent director. Dr. Young made the decision to resign from the board effective March 10, 2025. He has served on Novavax’s board since 2010 and as Chair since 2011. McGlynn has served on Novavax’s board of directors since 2020.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVAX:
- CDC plans study into potential vaccines, autism connections, Reuters reports
- Novavax (NVAX) Predicts Profitability by 2027 Despite Recent Stock Drop
- Novavax to Present Strategic Plans at Health Conference
- HHS increasing scrutiny of vaccines under RFK Jr., WSJ reports
- Dell reports mixed Q4 results, Intel delays Ohio chip factory: Morning Buzz
Questions or Comments about the article? Write to editor@tipranks.com